Prosperity Wealth Management Inc. Increases Position in Mesoblast Limited (NASDAQ:MESO)

Prosperity Wealth Management Inc. raised its holdings in Mesoblast Limited (NASDAQ:MESO) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 93,245 shares of the company’s stock after purchasing an additional 1,795 shares during the quarter. Mesoblast accounts for approximately 0.8% of Prosperity Wealth Management Inc.’s investment portfolio, making the stock its 22nd biggest holding. Prosperity Wealth Management Inc. owned 0.07% of Mesoblast worth $1,846,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Lindbrook Capital LLC boosted its holdings in Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after purchasing an additional 901 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after acquiring an additional 1,213 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Mesoblast during the 4th quarter worth about $30,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Mesoblast during the 4th quarter worth about $134,000. Finally, Pine Valley Investments Ltd Liability Co boosted its stake in shares of Mesoblast by 78.7% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 20,931 shares of the company’s stock worth $414,000 after acquiring an additional 9,217 shares in the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Finally, Cantor Fitzgerald upgraded shares of Mesoblast to a “strong-buy” rating in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Stock Performance

MESO opened at $13.28 on Wednesday. Mesoblast Limited has a twelve month low of $2.05 and a twelve month high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The company has a 50-day moving average price of $17.61 and a 200 day moving average price of $12.51.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.